Overview

Use of Tinzaparin for Anticoagulation in Hemodialysis

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The HEMO-TIN trial is designed to look at both the safety (bleeding risk) and effectiveness (clotting risk) of tinzaparin compared with unfractionated heparin for anticoagulation in hemodialysis patients.
Phase:
Phase 4
Details
Lead Sponsor:
Christine Ribic
Collaborators:
LEO Pharma
McMaster University
Treatments:
Calcium heparin
Dalteparin
Heparin
Heparin, Low-Molecular-Weight
Tinzaparin